332 related articles for article (PubMed ID: 25152576)
1. Involvement of eicosanoids in the pathogenesis of pancreatic cancer: the roles of cyclooxygenase-2 and 5-lipoxygenase.
Knab LM; Grippo PJ; Bentrem DJ
World J Gastroenterol; 2014 Aug; 20(31):10729-39. PubMed ID: 25152576
[TBL] [Abstract][Full Text] [Related]
2. The different inhibitory effects of Huang-Lian-Jie-Du-Tang on cyclooxygenase 2 and 5-lipoxygenase.
Li L; Zeng H; Shan L; Yuan X; Li Y; Liu R; Zhang W
J Ethnopharmacol; 2012 Sep; 143(2):732-9. PubMed ID: 22884869
[TBL] [Abstract][Full Text] [Related]
3. Cyclooxygenase/lipoxygenase shunting lowers the anti-cancer effect of cyclooxygenase-2 inhibition in colorectal cancer cells.
Ganesh R; Marks DJ; Sales K; Winslet MC; Seifalian AM
World J Surg Oncol; 2012 Sep; 10():200. PubMed ID: 23013454
[TBL] [Abstract][Full Text] [Related]
4. Celastrol modulates inflammation through inhibition of the catalytic activity of mediators of arachidonic acid pathway: Secretory phospholipase A
Joshi V; Venkatesha SH; Ramakrishnan C; Nanjaraj Urs AN; Hiremath V; Moudgil KD; Velmurugan D; Vishwanath BS
Pharmacol Res; 2016 Nov; 113(Pt A):265-275. PubMed ID: 27597642
[TBL] [Abstract][Full Text] [Related]
5. Flavocoxid, a dual inhibitor of cyclooxygenase-2 and 5-lipoxygenase, reduces pancreatic damage in an experimental model of acute pancreatitis.
Polito F; Bitto A; Irrera N; Squadrito F; Fazzari C; Minutoli L; Altavilla D
Br J Pharmacol; 2010 Nov; 161(5):1002-11. PubMed ID: 20977452
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma.
Rao CV; Janakiram NB; Madka V; Devarkonda V; Brewer M; Biddick L; Lightfoot S; Steele VE; Mohammed A
Oncotarget; 2015 Oct; 6(32):33290-305. PubMed ID: 26429877
[TBL] [Abstract][Full Text] [Related]
7. Effect of 5-LOX/COX-2 common inhibitor DHDMBF30 on pancreatic cancer cell Capan2.
Zhang B; Wang CL; Zhao WH; Lv M; Wang CY; Zhong WX; Zhou WY; Yu WS; Zhang Y; Li S
World J Gastroenterol; 2008 Apr; 14(16):2494-500. PubMed ID: 18442195
[TBL] [Abstract][Full Text] [Related]
8. Different forms of vitamin E and metabolite 13'-carboxychromanols inhibit cyclooxygenase-1 and its catalyzed thromboxane in platelets, and tocotrienols and 13'-carboxychromanols are competitive inhibitors of 5-lipoxygenase.
Park NY; Im S; Jiang Q
J Nutr Biochem; 2022 Feb; 100():108884. PubMed ID: 34710615
[TBL] [Abstract][Full Text] [Related]
9. Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells.
Ding XZ; Iversen P; Cluck MW; Knezetic JA; Adrian TE
Biochem Biophys Res Commun; 1999 Jul; 261(1):218-23. PubMed ID: 10405349
[TBL] [Abstract][Full Text] [Related]
10. Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway.
Tong WG; Ding XZ; Witt RC; Adrian TE
Mol Cancer Ther; 2002 Sep; 1(11):929-35. PubMed ID: 12481414
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of COX-2/mPGES-1 and 5-LOX in macrophages by leonurine ameliorates monosodium urate crystal-induced inflammation.
Liu Y; Duan C; Chen H; Wang C; Liu X; Qiu M; Tang H; Zhang F; Zhou X; Yang J
Toxicol Appl Pharmacol; 2018 Jul; 351():1-11. PubMed ID: 29763636
[TBL] [Abstract][Full Text] [Related]
12. Characterization of spirostanol glycosides and furostanol glycosides from anemarrhenae rhizoma as dual targeted inhibitors of 5-lipoxygenase and Cyclooxygenase-2 by employing a combination of affinity ultrafiltration and HPLC/MS.
Xie L; Lee DY; Shang Y; Cao X; Wang S; Liao J; Zhang T; Dai R
Phytomedicine; 2020 Oct; 77():153284. PubMed ID: 32707371
[TBL] [Abstract][Full Text] [Related]
13. High-throughput screening assays for cyclooxygenase-2 and 5-lipoxygenase, the targets for inflammatory disorders.
Kumar KA; Reddy TC; Reddy GV; Reddy DB; Mahipal SV; Sinha S; Gaikwad AN; Reddanna P
Indian J Biochem Biophys; 2011 Aug; 48(4):256-61. PubMed ID: 22053694
[TBL] [Abstract][Full Text] [Related]
14. Eicosanoid pathway in colorectal cancer: Recent updates.
Tuncer S; Banerjee S
World J Gastroenterol; 2015 Nov; 21(41):11748-66. PubMed ID: 26557000
[TBL] [Abstract][Full Text] [Related]
15. Synthetically-tailored and nature-derived dual COX-2/5-LOX inhibitors: Structural aspects and SAR.
Meshram MA; Bhise UO; Makhal PN; Kaki VR
Eur J Med Chem; 2021 Dec; 225():113804. PubMed ID: 34479036
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of 5-Lipoxygenase-Derived Leukotrienes and Hemiketals as a Novel Anti-Inflammatory Mechanism of Urolithins.
Giménez-Bastida JA; González-Sarrías A; Espín JC; Schneider C
Mol Nutr Food Res; 2020 Jun; 64(11):e2000129. PubMed ID: 32306507
[TBL] [Abstract][Full Text] [Related]
17. Novel di-tertiary-butyl phenylhydrazones as dual cyclooxygenase-2/5-lipoxygenase inhibitors: synthesis, COX/LOX inhibition, molecular modeling, and insights into their cytotoxicities.
Ghatak S; Vyas A; Misra S; O'Brien P; Zambre A; Fresco VM; Markwald RR; Swamy KV; Afrasiabi Z; Choudhury A; Khetmalas M; Padhye S
Bioorg Med Chem Lett; 2014 Jan; 24(1):317-24. PubMed ID: 24295787
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel hybrids of diaryl-1,2,4-triazoles and caffeic acid as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase for cancer therapy.
Cai H; Huang X; Xu S; Shen H; Zhang P; Huang Y; Jiang J; Sun Y; Jiang B; Wu X; Yao H; Xu J
Eur J Med Chem; 2016 Jan; 108():89-103. PubMed ID: 26638042
[TBL] [Abstract][Full Text] [Related]
19. Enhancing antitumor effects in pancreatic cancer cells by combined use of COX-2 and 5-LOX inhibitors.
Ding X; Zhu C; Qiang H; Zhou X; Zhou G
Biomed Pharmacother; 2011 Oct; 65(7):486-90. PubMed ID: 21993002
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of the 5-lipoxygenase pathway in atherosclerosis.
Bäck M
Curr Pharm Des; 2009; 15(27):3116-32. PubMed ID: 19754386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
